Cardiac tumors medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
|- | |- | ||
| '''[[Cardiac Lymphoma]]''' || Rituximab is an '''[[anti-CD20 monoclonal antibody]]''' that typically produces remission in a wide range of B-cell non-Hodgkin lymphomas. | | '''[[Cardiac Lymphoma]]''' || Rituximab is an '''[[anti-CD20 monoclonal antibody]]''' that typically produces remission in a wide range of B-cell non-Hodgkin lymphomas. | ||
MOA: Activation of antibody-dependent, [[cell-mediated cytotoxicity]], [[complement-mediated lysis]], [[phagocytosis]] of antibody-coupled tumor cells, and activation of cell death appear to constitute its mode of action. | MOA: Activation of antibody-dependent, [[cell-mediated cytotoxicity]], [[complement-mediated lysis]], [[phagocytosis]] of antibody-coupled tumor cells, and activation of cell death appear to constitute its mode of action.<ref name="pmid14745155">{{cite journal| author=Nakagawa Y, Ikeda U, Hirose M, Ubukata S, Katsuki TA, Kaminishi Y | display-authors=etal| title=Successful treatment of primary cardiac lymphoma with monoclonal CD20 antibody (rituximab). | journal=Circ J | year= 2004 | volume= 68 | issue= 2 | pages= 172-3 | pmid=14745155 | doi=10.1253/circj.68.172 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14745155 }} </ref> | ||
|} | |} | ||
Revision as of 00:13, 19 May 2022
|
Cardiac tumors Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cardiac tumors medical therapy On the Web |
|
American Roentgen Ray Society Images of Cardiac tumors medical therapy |
|
Risk calculators and risk factors for Cardiac tumors medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Template:Dj
Overview
Most of the Cardiac tumors are treated with surgical management. Medical treatment has been used as adjuvant chemotherapy or in small isolated tumors.
Medical Treatment of Cardiac Tumors
| Tumor | Treatment |
|---|---|
| Cardiac Lymphoma | Rituximab is an anti-CD20 monoclonal antibody that typically produces remission in a wide range of B-cell non-Hodgkin lymphomas.
MOA: Activation of antibody-dependent, cell-mediated cytotoxicity, complement-mediated lysis, phagocytosis of antibody-coupled tumor cells, and activation of cell death appear to constitute its mode of action.[1] |
References
- ↑ Nakagawa Y, Ikeda U, Hirose M, Ubukata S, Katsuki TA, Kaminishi Y; et al. (2004). "Successful treatment of primary cardiac lymphoma with monoclonal CD20 antibody (rituximab)". Circ J. 68 (2): 172–3. doi:10.1253/circj.68.172. PMID 14745155.